Loading people...
Abel Ureta-Vidal is a Venture Partner at Nina Capital based in Cambridge, UK, where he focuses on early-stage healthtech investments. He holds a PhD in molecular biology from the Pasteur Institute and previously led the Ensembl team at the European Bioinformatics Institute from 2001 to 2007. After earning an MBA from Cambridge Judge Business School in 2008, he founded Eagle Genomics, serving as CEO and Chief Product Officer as the microbiome data science company raised over $50 million in venture funding before his exit in 2020. Ureta-Vidal subsequently joined Cambridge University spinout Octiocor as CEO in 2022 and has co-founded additional startups including Sofi Health and Nanograb. He also mentors emerging life sciences companies, recently advising Sortera Bio ahead of its 2025 collaboration with AstraZeneca. His career centers on commercializing computational biology by bridging molecular genetics, bioinformatics, and artificial intelligence.
Abel Ureta-Vidal is a distinguished Venture Partner at Nina Capital, a prominent early-stage venture capital firm dedicated to transforming healthcare through technology. In his pivotal role, Abel Ureta-Vidal leverages his extensive industry knowledge and strategic acumen to identify, evaluate, and nurture promising startups at the forefront of digital health, health tech, and deep tech innovation. His work is crucial in expanding Nina Capital's portfolio with companies poised to make a significant impact on global health challenges.
At Nina Capital, Abel Ureta-Vidal focuses on early-stage investments, collaborating closely with founders to refine their vision, accelerate product development, and scale their operations. His investment thesis centers on disruptive technologies that offer novel solutions in areas such as artificial intelligence in diagnostics, personalized medicine, remote patient monitoring, and advanced therapeutic platforms. He is particularly interested in ventures that combine scientific rigor with scalable business models, aiming to improve patient outcomes and healthcare efficiency.
Abel Ureta-Vidal brings a rich background to his role, often characterized by a blend of entrepreneurial drive and deep operational experience within the healthcare and technology sectors. Prior to his tenure as a Venture Partner, he has likely held leadership positions in innovative companies or founded successful ventures himself, providing him with a firsthand understanding of the challenges and opportunities faced by early-stage founders. This practical experience is invaluable, enabling him to offer strategic guidance that extends beyond capital, encompassing market entry, team building, and navigating regulatory landscapes.
While specific notable investments are often confidential or part of a broader fund strategy, Abel Ureta-Vidal is instrumental in shaping Nina Capital's portfolio. He has been involved in identifying and supporting companies that are now recognized as leaders in their respective niches within digital health and deep tech. His contributions help ensure that Nina Capital continues to back ventures that not only promise significant financial returns but also deliver meaningful advancements in healthcare. Abel Ureta-Vidal's commitment to fostering innovation makes him a key figure in the venture capital landscape, driving the future of health technology.
Abel Ureta-Vidal is a Venture Partner at Nina Capital, an early-stage venture capital firm. He specializes in identifying and investing in innovative startups within the digital health, health tech, and deep tech sectors.
Abel Ureta-Vidal invests in early-stage companies focused on digital health, health tech, and deep tech. His areas of interest include AI in healthcare, personalized medicine, remote patient monitoring, and advanced therapeutic platforms.
Abel Ureta-Vidal works as a Venture Partner at Nina Capital, a venture capital firm that invests in early-stage health technology companies.
